✦ LIBER ✦

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial

✍ Scribed by Cunningham, David; Lang, Istvan; Marcuello, Eugenio; Lorusso, Vito; Ocvirk, Janja; Shin, Dong Bok; Jonker, Derek; Osborne, Stuart; Andre, Niko; Waterkamp, Daniel; Saunders, Mark P

Book ID: 121270620
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 367 KB
Volume: 14
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(13)70154-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Capecitabine and cisplatin with or witho

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

✍ Lordick, Florian; Kang, Yoon-Koo; Chung, Hyun-Cheol; Salman, Pamela; Oh, Sang Ch 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 323 KB

Leucovorin, fluorouracil, and oxaliplati

Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial

✍ Yamada, Yasuhide; Takahari, Daisuke; Matsumoto, Hiroshi; Baba, Hideo; Nakamura, 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 438 KB

Epirubicin, oxaliplatin, and capecitabin

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

✍ Waddell, Tom; Chau, Ian; Cunningham, David; Gonzalez, David; Okines, Alicia Fran 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 396 KB

FOLFIRI plus cetuximab versus FOLFIRI pl

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

✍ Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexa 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 289 KB

FOLFIRI plus cetuximab versus FOLFIRI pl

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

✍ Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexa 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 289 KB

FOLFIRI plus cetuximab versus FOLFIRI pl

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

✍ Heinemann, Volker; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexa 📂 Article 📅 2014 🏛 Lancet Publishing Group 🌐 English ⚖ 289 KB

## Background: Cetuximab and bevacizumab have both been shown to improve outcomes in patients with metastatic colorectal cancer when added to chemotherapy regimens; however, their comparative effectiveness when partnered with first-line fluorouracil, folinic acid, and irinotecan (folfiri) is unknow